Current opinion in organ transplantation · 2026
Is the Banff Human Organ Transplant panel ready for prime time?
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papamanoli Agni, Groningen Marian C Clahsen-van, Rosales Ivy A
Аннотация
PURPOSE OF REVIEW: The Banff Human Organ Transplant (B-HOT) panel was developed to enable standardized targeted transcriptomic assessment of formalin-fixed paraffin-embedded (FFPE) transplant biopsies across centers and organs. As literature has now moved beyond proof-of-principle studies, it is time to examine whether B-HOT is ready for routine clinical use and in what context.
RECENT FINDINGS: The literature is dominated by retrospective studies using archival FFPE kidney transplant biopsies. Data support use of B-HOT for diagnostic refinement of antibody-mediated (AMR) rejection, especially in biopsies with incomplete, borderline, or threshold-limited phenotypes. Studies also suggest value for prognostic enrichment and clarification of diagnostically challenging Banff phenotypes. Cross-organ applications in heart and uterus transplantation, as well as exploratory mechanistic studies in placenta-associated rejection biology, and xenotransplantation, support the panel's translatability. Emerging implementation-oriented studies include sparse classifiers, multiclass models, and automated reporting frameworks.
SUMMARY: The strongest readiness evidence is for adjunctive use in kidney rejection classification, particularly AMR and threshold-limited or incomplete phenotypes. However, broader routine implementation remains limited by challenges related to threshold harmonization, cross-platform standardization, and per-biopsy heterogeneity. Prospective clinical utility studies are needed to determine whether B-HOT-guided management improves treatment decisions and graft outcomes.
RECENT FINDINGS: The literature is dominated by retrospective studies using archival FFPE kidney transplant biopsies. Data support use of B-HOT for diagnostic refinement of antibody-mediated (AMR) rejection, especially in biopsies with incomplete, borderline, or threshold-limited phenotypes. Studies also suggest value for prognostic enrichment and clarification of diagnostically challenging Banff phenotypes. Cross-organ applications in heart and uterus transplantation, as well as exploratory mechanistic studies in placenta-associated rejection biology, and xenotransplantation, support the panel's translatability. Emerging implementation-oriented studies include sparse classifiers, multiclass models, and automated reporting frameworks.
SUMMARY: The strongest readiness evidence is for adjunctive use in kidney rejection classification, particularly AMR and threshold-limited or incomplete phenotypes. However, broader routine implementation remains limited by challenges related to threshold harmonization, cross-platform standardization, and per-biopsy heterogeneity. Prospective clinical utility studies are needed to determine whether B-HOT-guided management improves treatment decisions and graft outcomes.